Schering AG/Epix Contrast Agent Vasovist Gains EU Approval, Waits For FDA

Vasovist (formerly MS-235) has a U.S. user fee date of Nov. 23; FDA had requested efficacy data from new clinical trials.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet